Target intelligence / Profile preview

Flavivirus envelope glycoprotein (E protein) (E protein)

Target
E protein
Molecular classification
Viral surface protein, Class II viral fusion protein, Glycoprotein
01

Overview

The Flavivirus envelope (E) glycoprotein is the principal surface component of viruses within the Flaviviridae family, including Dengue, Zika, and West Nile viruses (Pierson & Diamond, 2020, Nature Microbiology). It is a class II viral fusion protein that mediates the critical initial steps of infection, including attachment to host cell receptors and subsequent fusion between the viral and endosomal membranes (Rey et al., 1995, Nature). Structurally, the E protein is organized as homodimers on the surface of mature virions, which reorganize into trimers upon exposure to the acidic environment of the endosome to trigger the fusion process (Modis et al., 2004, Nature). Because it is the primary target for neutralizing antibodies, the E protein is the central focus for the development of vaccines and therapeutic monoclonal antibodies (Heinz & Stiasny, 2012, Vaccine). However, a significant challenge in targeting this protein is antibody-dependent enhancement (ADE), where non-neutralizing or sub-neutralizing antibodies can facilitate viral entry into immune cells via Fc receptors, potentially worsening the disease (Katzelnick et al., 2017, Science). This phenomenon is particularly relevant for Dengue virus, where cross-reactive antibodies from a previous infection with a different serotype can lead to severe dengue hemorrhagic fever.

Other names
Envelope proteinE glycoproteinFlavivirus E proteinViral envelope protein
02

Mechanism of action

Neutralization of viral particles by blocking receptor attachment or inhibiting the pH-dependent conformational change required for membrane fusion (Heinz & Stiasny, 2012, Vaccine).

03

Biological functions

Viral attachmentReceptor bindingMembrane fusionViral assemblyHemagglutination
04

Disease associations

Dengue feverZika virus infectionWest Nile feverYellow feverJapanese encephalitisTick-borne encephalitis
05

Safety considerations

Antibody-dependent enhancement (ADE)Cross-reactivity leading to diagnostic interferenceVaccine-induced enhancement of disease in seronegative individuals
06

Interacting drugs

Dengvaxia (CYD-TDV)

6 more in the full profile.

07

Biomarkers

Neutralizing antibody titers (PRNT50)E-protein specific IgG levelsE-protein specific IgM levelsViral RNA load

Beyond the preview

Go deeper on Flavivirus envelope glycoprotein (E protein) (E protein).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flavivirus envelope glycoprotein (E protein) (E protein).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call